Replies to post #55594 on $Pistol Pete$, $Mick$ & Friends Stock Picks /news,

[$Pistol Pete$]

$GRLI Glori Energy to Present at the 28th Annual ROTH Conference

Source: PR Newswire (US)
HOUSTON, March 10, 2016 /PRNewswire/ -- Glori Energy Inc. (NASDAQ: GLRI), an energy technology and oil production company focused on enhanced oil recovery using its proprietary AERO® System, today announced that the Company's management will participate in the 28th Annual ROTH Conference to be held in Dana Point, California on March 13-16, 2016.

Stuart Page, Chief Executive Officer, and Dr. Michael Pavia, Chief Technology Officer, are scheduled to present on Monday, March 14 at approximately 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time). On the morning of the presentation, a link to the presentation materials will be available in the Investor Relations section of the Company's website at www.glorienergy.com.

ABOUT GLORI ENERGY INC.

Glori Energy is a Houston-based energy technology and oil production company that deploys its proprietary AERO technology to increase the amount of oil that can be produced from conventional oil fields. Glori owns and operates oil fields onshore U.S. and additionally provides its technology as a service to E&P companies globally. Only one-third of all oil discovered in a typical reservoir is recoverable using conventional technologies; the rest remains trapped in the rock. Glori's proprietary AERO System recovers residual oil by stimulating a reservoir's native microorganisms to sustainably increase the ultimate recovery at a low cost. For more information, visit www.GloriEnergy.com.

Glori Energy Contact
Victor M. Perez
Chief Financial Officer
713-237-8880
[e-mail]

Investor Relations Counsel
Lisa Elliott / Anne Pearson
Dennard-Lascar Associates
713-529-6600
[e-mail]
[e-mail]





To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/glori-energy-to-present-at-the-28th-annual-roth-conference-300233854.html

SOURCE Glori Energy Inc.


Copyright 2016 PR Newswire

[$Pistol Pete$]

$GLRI 15' Chart

[$Pistol Pete$]

$GLRI Daily Chart

[$Pistol Pete$]

$GLRI Daily and Weekly Charts

[$Pistol Pete$]

$GLRI Weekly Chart

[$Pistol Pete$]

$GLRI Technical Analysis

http://www.stockta.com/cgi-bin/analysis.pl?symb=GLRI&cobrand=&mode=stock

[$Pistol Pete$]

$GLRI ~ Glori Energy Inc due diligence report

$GLRI recent news/filings

https://finance.yahoo.com/q/h?s=GLRI+Headlines

$GLRI charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com


$GLRI company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/GLRI/company-info
Ticker: $GLRI
OTC Market Place: Not Available
CIK code: 0001597131
Company name: Glori Energy Inc
Incorporated In: DE, USA

$GLRI share structure

## source: otcmarkets.com

Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: Not Available
$GLRI extra dd links

Company name: Glori Energy Inc
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/GLRI/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/GLRI/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=GLRI+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=GLRI+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=GLRI+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/GLRI/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/GLRI/news - http://finance.yahoo.com/q/h?s=GLRI+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/GLRI/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/GLRI/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/GLRI/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/GLRI/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/GLRI/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/GLRI/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/GLRI/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/GLRI/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=GLRI+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/GLRI
DTCC (dtcc.com): http://search2.dtcc.com/?q=Glori+Energy+Inc&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Glori+Energy+Inc
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Glori+Energy+Inc&x=0&y=0

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/GLRI/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/GLRI
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/GLRI/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/GLRI/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/GLRI/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001597131&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/GLRI/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/GLRI/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/GLRI/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/GLRI/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=GLRI&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=GLRI
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/GLRI/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=GLRI+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=GLRI+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=GLRI
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=GLRI
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=GLRI+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/GLRI/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=GLRI+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/GLRI.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=GLRI
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/GLRI/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/GLRI/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/GLRI/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/GLRI/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/GLRI
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/GLRI
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/GLRI:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=GLRI
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=GLRI

[$Pistol Pete$]

$LEU Daily and Weekly Charts

[$Pistol Pete$]

$OHRP Daily & Weekly Chart

[$Pistol Pete$]

$PSUN 15' Chart

[$Pistol Pete$]

$PSUN Technical Analysis

http://www.stockta.com/cgi-bin/analysis.pl?symb=PSUN&cobrand=&mode=stock

[$Pistol Pete$]

$PSUN 3 months chart

[$Pistol Pete$]

$SFOR Technical Analysis

http://www.stockta.com/cgi-bin/analysis.pl?symb=SFOR&cobrand=&mode=stock

[$Pistol Pete$]

$SFOR Broad Street Alerts Issues Watch List and Due Diligence Report’s

Source: InvestorsHub NewsWire
NEW YORK, NY – April 18th, 2016 -- Investors Hub NewsWire – http://www.BroadStreetAlerts.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals www.Broadstreetalerts.com is often on the lookout for either large investor relations campaigns being deployed or stocks gaining momentum.

To subscribe by phone and receive messages directly to your mobile phone in real time, text keyword "Alerts" to 25827.

We believe the following companies could be getting some attention in the near future follow the links for the full report.

Skyline Medical Inc. (NASDAQ: SKLN)
Skyline Medical Inc. has a fully automated, patented, and FDA cleared surgical fluid disposal devices - the STREAMWAY System - that virtually eliminates operating room worker’s exposure to blood, irrigation fluid and other potentially infectious fluids found in the surgical environment. Full report- http://broadstreetalerts.com/nkln-nwbo-amrn-sfor-reports/


Strikeforce Technologies, Inc. (OTCMKT: SFOR)
StrikeForce Technologies provides a suite of online products that help prevent cyber theft and data breaches by protecting customers, employees and partners in real time at every vulnerable point. Its products prevent fraud during account creation, account access, transactions and changes, and transaction verification, saving businesses millions of dollars, offering new levels of customer protection, and strengthening their brand names. Full report- http://broadstreetalerts.com/nkln-nwbo-amrn-sfor-reports/

Northwest Biotherapeutics, Inc. (NASDAQ: NWBO)
Northwest Biotherapeutics, Inc. is a development stage biotechnology company focused on discovering, developing and commercializing immunotherapy products that generate and enhance immune system responses to treat cancer. The Company operates in the United States and is incorporated in Delaware, USA. Full report- http://broadstreetalerts.com/nkln-nwbo-amrn-sfor-reports/

Amarin Corp. Plc (NASDAQ: AMRN)
Amarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. The companys lead product includes Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It is also involved in developing Vascepa for the treatment of patients with high triglyceride levels who are also on statin therapy for elevated low-density lipoprotein cholesterol levels. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was founded in 1989 and is based in Dublin, Ireland. Full report- http://broadstreetalerts.com/nkln-nwbo-amrn-sfor-reports/


About Broad Street Alerts
We make the connection between sophisticated investors and high quality micro and small cap companies. An issuer of reports that provide a straightforward assessment of the profiled company. They include stocks traded in the NYSE, NASDAQ, and OTCBB exchanges.

Safe Harbor Statement
This press release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to anticipated revenues, expenses, earnings, operating cash flows, the outlook for markets and the demand for products. Forward-looking statements are no guarantees of future performance and are inherently subject to uncertainties and other factors which could cause actual results to differ materially from the forward-looking statements. Such statements are based upon, among other things, assumptions made by, and information currently available to, management, including management's own knowledge and assessment of the Company's industry and competition. The Company refers interested persons to its most recent Annual Report on Form 10-K and its other SEC filings for a description of additional uncertainties and factors, which may affect forward-looking statements. The company assumes no duty to update its forward-looking statements

Compliance Procedure
Content is researched, written and reviewed on a best-effort basis by a 3rd party research analyst. However, we are only human and may make mistakes. This report was prepared for informational purposes only. A full disclaimer can be found by viewing the full analyst report. We do not hold any positions and have not been compensated in any form for this press release and coinciding reports. For more information and services provided beyond this press release please use contact information provided below. If you notice any errors or omissions, please notify us.

Source: Broad Street Alerts

Contact: [e-mail]

[$Pistol Pete$]

What are you working on?

[$Pistol Pete$]

$SFOR One Year Chart

[$Pistol Pete$]

$SFOR 6 months chart

[$Pistol Pete$]

$BSSP How does IPF work?





IPF binds to T-cells and turns on Th1 immune system responses that kill infected cells. IPF appears to modulate helper T1 cells’ expression of elaborate cytokines INFy, IL-2, which selectively promote cell-mediated immune response and subsequently stimulate cytotoxic lymphocytes. These lymphocytes have a prominent role in the host’s immunologic response to the infection. Proteins encoded by these pathogens enter the endogenous pathway for antigen presentation and are expressed on the surface of the infected cell as a complex with class I MHC –proteins. IPF appears to present a novel mechanism to reduce viral burden and stimulate innate immune responses to the virus for patients with significant antiretroviral resistance.

Not done by any other immune therapy.

Cantech Pharma is a drug development company committed to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases.
It is committed to creating drugs for the better health of mankind.
Our flagship compound is a suspension of Inactivated Pepsin Fraction (IPF), which studies have shown is effective in thetreatment of autoimmune diseases such as cancer, cirrhosisand Hepatitis C. IPF is the active drug substance of ITP and is a purified extract of porcine pepsin. ITP has been shown to modulate the immune system.

[$Pistol Pete$]

$BSSP Trader's Cheat Sheet

http://www.barchart.com/cheatsheet.php?sym=BSSP

[$Pistol Pete$]

$SFOR Trader's Cheat Sheet

http://www.barchart.com/cheatsheet.php?sym=SFOR

[$Pistol Pete$]

$BSSP Cantech Holding, Inc. (BSSP) Announces Formal Negotiations for LOI/Business Collaboration With Zelor S.A.P.I., Mexico



MONROVIA, CA -- (Marketwired) -- 08/19/16 -- Cantech Holding, Inc., formerly Reve Technologies, Inc., (OTC PINK: BSSP) (the "Company" or "Cantech") a development stage immunotherapeutic based technology company today announced it has received a Letter of Intent which proposes a business collaboration with newly formed Institute of Medicine of the conservation ZELOR S.A.P.I., located in Tijuana, B.C., Mexico ("Zelor").

After ongoing discussions on August 16, 2016 the Company received a letter of intent from Zelor who is involved with scientific research on biotechnology field specializing in human health. Zelor has expressed interest standing ready to discuss business collaboration and terms for processing and/or manufacturing of Cantechs spotlight product called Immune Therapeutic Protein as well as specific process and/or requirements for the Company's objectives. Zelor describes their terms of collaboration attractive and facilities accommodating including state of the art equipment and GMP (good manufacturing practices) all around. Company management will attend the now scheduled formal meeting in Mexico early next week. The onsite visit to include to view and inspect the facilities while attending the formal negotiations for the proposed business collaboration agreement between the Company and Zelor which have been discussed to include the processing and/or manufacture for commercialization of its spotlight product utilizing Zelors facilities and utilizing its permit for Mexico.

The Company notes it will additionally pursue the completion for obtaining its own permit in progress for over eight months now but believes that the business collaboration with Zelor upon completion steps up and provides for the sooner immediate entry to the markets for initiation of the Companys spotlight product in Mexico.

Further the Company reports that it is also in negotiations to obtain licensing from a Company that has an FDA, Medicare and Medi Cal approved medical device technology for non-invasive cardio vascular testing procedures and other important medical testing applications.

The Company previously reported launching its new corporate identity as Cantech to reflect is new business strategy. The name represents the fusion of an innovative approach regarding its commitment to improving lives by helping to bring impactful immunotherapeutic treatment(s) to market initially in Mexico for cancer indication.

The Company previously reported it was in process of obtaining an assignment for a new cusip number in connection with the name change, and its submission of a corporate action with FINRA toward gaining approval regarding a new ticker symbol for the Company as soon as practicable and plans to announce any effective date for such change in a future release or current report. The corporate action included the Company changing both its name to Cantech Holding, Inc. from Reve Technologies, Inc. along with changing its corporate domicile to Wyoming from Nevada which all became effective on May 27, 2016, and provided for a voluntary symbol change requested. The Company further notes that its filings going forward on the next filing with the SEC will also track under the new name Cantech Holding, Inc. On August 5, 2016 the Company received notice from FINRA summarily that after review of the corporate action including all materials submitted, and including its periodic reports, that in accordance with FINRA rule 6490 it was deficient under said rule citing the Company being delinquent in two of its periodic reports for the period ended December 31, 2015, and for the period ended March 31, 2016. Once the filing deficiencies have been cured the Company may resubmit the corporate action which would then upon any subsequent approval allow OTC markets to finally recognize the name change that presently exists everywhere else (already effective in Wyoming and on the next filing to the SEC EDGAR database) along with providing for a new symbol to match. Noting, the Company believes it has encountered difficulties through the review period from certain potential investors that would have assisted much earlier the additional financing necessary to assist curing the delinquencies and provide additional working capital for Company operations but however required the symbol and name be processed simply to match its new business operations and Cantech name going forward for the OTC markets which the Company believes is logical. The Company will endeavor to proceed forward with these obstacles as best possible.

About Canteck Pharma, Inc. IPF for Cancer treatment

Immunotherapy has the potential to provide an alternative and/or complementary treatment in combination with other immune base therapy for several types of cancer. The advantage of immunotherapy over radiation and chemotherapy is that it can act specifically against the tumor without causing normal tissue damage. Current data indicates that immune protection against all cancer requires the generation of a potent cellular immune response against a unique tumor antigen expressed by the malignant cell. As a consequence successful immune protection first requires a unique antigen expressed in the tumor cells (tumor specific antigen) and second, an induction of a potent T-cell immune response, targeted to the tumor antigen.

Unfortunately the immune system by itself can't recognize specific tumor antigens and reject them; however recent advances have revealed that certain proteins binding with specific tumor antigens can be recognized by the immune system, this is what IPF does.

IPF proteins attach to tumor antigens, creating super-antigens (Sags), which increases the number of antibodies against the malignant cells and induces a potent T-cell immune response targeted to the tumor antigen. For a stronger immune response, IPF may be paired with different kinds of adjuvants such as IL-2, IL-6, IL-12 or other cytokines. Another form of immunotherapy can also provide active immunization, which allows for amplification of the immune response. In addition, vaccines can generate a memory immune response. Recent advances have revealed that any cellular protein (expressed in virally infected cells or cancer cells) can be recognized by the immune system if those proteins are presented to the immune system in a form that results in an activation rather than ignorance or tolerance to the antigen. In addition, T-cells rather than B-cells are usually responsible for this recognition.

It is important to point out that when we discuss vaccines for cancer we are referring to treatment rather than prevention, because the antigens expressed by tumor cells (which are the immunogens recognized by the immune system) are not yet known. Attaching known proteins will increase the number of antibodies to fight against them.

This mechanism of action will give us an exact answer (known antigens we have to make known for immune system). In contrast we can use vaccines to prevent infectious diseases because the antigens expressed the causative agent -- fraction and/or its proteins that can attach, serve as the immunogen are already known.

About Cantech Holding, Inc. (f/k/a Reve Technologies, Inc.)

The Company was incorporated on May 11, 2010 (Date of Inception) under the laws of the State of Nevada, as Bassline Productions, Inc. On March 21, 2014 the Company amended its articles of incorporation and changed its name to Reve Technologies, Inc. and investing to develop and market emerging hardware, mobile and web applications later establishing a new Capital Purchase Division. The Company is now a transitioning forward with the acquisition of an Exclusive License Agreement for Patented Technology for Irreversible Pepsin Fraction (IPF) specific to the Cancer indication only, for Mexico with privately held immune-oncology and Therapeutics company. Through the terms for the Company's Exclusive Sub Licensing Agreement with Canteck Pharma, Inc. we will focus on the development, manufacture and commercialize our lead product Irreversible Pepsin Fraction (IPF) specific to the Cancer indication only, for Mexico. The Company changed its name to Cantech Holding, Inc. effective on May 27, 2016 and its domicile to Wyoming from Nevada also effective on May 27, 2016.

This release contains statements that constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements appear in a number of places in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of Cantech Holding, Inc., its directors or its officers with respect to, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; (iii) growth strategy and operating strategy. The words "may," "would," "will," "expect," "estimate," "can," "believe," "potential" and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond Cantech Holding, Inc.'s ability to control, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors. More information about the potential factors that could affect the business and financial results is and will be included in Cantech Holding, Inc.'s filings with the Securities and Exchange Commission.

Public Relations and Shareholder Information

Name:
Dennis Alexander
Phone: [phone]
Email: [e-mail]

Source: Cantech Holding, Inc.

[$Pistol Pete$]

$BSSP nice news and lets see how she will be trading next week

http://www.barchart.com/headlines/story/480398/cantech-holding-inc-bssp-announces-formal-negotiations-for-loi-business-collaboration-with-zelor-s-a-p-i-mexico

Go $BSSP